Giant gastric gastrointestinal stromal tumors

Abstract

Introduction: Gastrointestinal stromal tumors (GIST) represent 0.1-3% of all mesenchymal neoplasms of the gastrointestinal tract and giant gastric (GG) GIST are rare. Purpose: Study of clinical, histopathological and immunohistochemical features and treatment results of GG GIST. Material and methods: 92 cases with GG GIST (c-kit(CD117)(+) treated between 2007-2019. Conclusions: GG GIST are rare, but possess a higher risk of progression. Complex treatment is the best curative option. Keywords: giant GIST, complex treatment, high risk. Results: A review of the database of 92 gastric GIST patients with positivity to the specific marker c-KIT(CD117) was performed. The study group consisted of 14 patients with GIST of the stomach. M:F=1.8:1. Mean age-59.78±2.35 years. Surgical options: excision of gastric tumor-2 (14,3%), gastric wedge resection - 7 (50%), partial gastrectomy - 5 (35,7%). The mean maximum size of tumors was 23.69±0.81 cm. Immunohistochemical phenotype: CD117(+)-14(100%), CD34(+) -12(85.7%), desmin(+)-3(21.4%), vimentin(+)-10(71.4%). Mean number of mitoses–24.36±6.3. Tumors with high mitotic count were registered more frequent than with low mitotic count – 11(78.6%) vs. 3(21.4%) (p<0.05). Metastases at first presentation – 28.6%(n=4) cases. Complex treatment – surgery and imatinib mesylate–in 14(100%) patients. Conclusions: GG GIST are rare, but possess a higher risk of progression. Complex treatment is the best curative option.